Diagnostics
-
How Genome Sequencing Can Broaden the Scope of Newborn Screening
Standard newborn screening can detect dozens of inherited diseases, but genomics technology enables testing for hundreds of them. A North Carolina program evaluating the feasibility of bringing genomics to newborn screening is expanding with an initial goal of testing 5,000 babies in the next year.
-
Devices & Diagnostics, Sponsored Post
Diagnostic Testing Landscape Paves the Way for Consumer Centric Approach to Disease Detection
The Covid-19 pandemic changed the way we think of the role of diagnostics not only for clinicians but also consumers. The pandemic propelled innovation of in vitro diagnostics and the at-home test kits space for chronic conditions, sexual health, and more.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Devices & Diagnostics, BioPharma
Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.
-
MedCity INVEST Ask the Investor Spotlight: Yaniv Sneor of Mid Atlantic Bio Angels
Yaniv Sneor, the co-founder of Mid Atlantic Bio Angels and part of the Ask the Investor sessions at MedCity INVEST this week, explained what his firm looks for in life science startups.
-
Startup Function Oncology Aims to Make CRISPR Part of Next Revolution in Cancer
Function Oncology goes beyond next-generation sequencing with a CRISPR-based technology that identifies targets for a patient’s cancer regardless of whether or not they are mutated. Now out of stealth, the company will present data validating its approach during the American Association for Cancer Research annual meeting.
-
Devices & Diagnostics, BioPharma, Legal
FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition
The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.
-
The Vibe at ViVE: A Progress Report on Healthcare Transformation
Hear from healthcare executives such as Nicholas Turos, vice president of business development with Babson Diagnostics, Marcus Perez, Altera Digital Health president, and Integra Connect COO Cory Wiegert on how they are meeting the challenges of healthcare innovation.
-
Devices & Diagnostics, Sponsored Post
The Covid-19 Pandemic Has Served as a Catalyst for Diagnostic Transformation
The Covid-19 pandemic has transformed the way we think of diagnostics in our daily lives. In a recent webinar, BD Vice President for Diagnostics Nikos Pavlidis spoke with a clinician and an epidemiologist where they shared their perspectives on how testing developments have changed the way we track respiratory illnesses.
-
Perspectum Completes $55M Series C to Improve Metabolic Disease Diagnosis
Perspectum — a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer — recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
FDA Authorizes First Covid-19 and Flu Test, But Its Maker Files for Bankruptcy
Lucira Health now has the first FDA authorized diagnostic that detects the novel coronavirus and influenza in a single test. But the regulatory decision comes too late for the diagnostics developer, which has filed for bankruptcy protection.
-
Devices & Diagnostics, Sponsored Post
How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19
A webinar sponsored by BD scheduled for March 7 will explore how diagnostics companies are working with healthcare organizations to guard against the perfect storm of Covid-19, RSV and influenza. Register today!
-
BioPharma, Consumer / Employer, Devices & Diagnostics, Employee Benefits, Health Services, Health Tech, Startups, SYN
Apply to MedCity INVEST Pitch Perfect Where Investment Trends and Innovation Converge
In the runup to INVEST and the startup pitch contest, we highlight trends in investment and innovation across bipharma, diagnostics, medical devices, health tech: payer/provider, and health tech: consumer/employer. The deadline has been extended until February 28 and finalists will be announced March 31. Apply today!
-
Time Is Running Out to Apply for MedCity’s Largest Pitch Contest of the Year
With five tracks of startups across healthcare and life sciences, INVEST Pitch Perfect, scheduled for May 22-24 at the Ritz Carlton in Chicago, is MedCity’s largest startup pitch contest of the year.
-
StartUPDATES: New Developments from Healthcare Startups
Check out news from BioMEMS Diagnostics, Rx Redefined, Ferrum Health and Avanlee Care.
-
The Care I Wish Our Parents Had
As a daughter who has been through the wringer a few times, I write today to all health care leaders trying to build a better future.